Feb 03, 2016 14:00 pm UTC| Business
ATLANTA, Feb. 03, 2016 -- Manhattan Associates, Inc. (NASDAQ:MANH) today announced that Boston Retail Partners, a retail management consulting firm, has joined its Manhattan Value Partner (MVP) partner program as a...
VerifyMe Initiates the Release of Version 2.0 With Developer Portal Launch
Feb 03, 2016 13:44 pm UTC| Business
NEW YORK, Feb. 03, 2016 -- VerifyMe, Inc. (OTCBB:VRME), a pioneer in patented physical, cyber and biometric technology solutions that prevent identity theft, counterfeiting and fraud, today initiated the release of...
Casella Waste Systems, Inc. Announces Permit Expansion at the Ontario County Landfill
Feb 03, 2016 13:41 pm UTC| Business
RUTLAND, Vt., Feb. 03, 2016 -- Casella Waste Systems, Inc. (Nasdaq:CWST), a regional solid waste, recycling and resource management services company, announced that the New York State Department of Environmental...
Hemispherx Biopharma Introduces a Voluntary Stock Purchase Plan to Create Shareholder Value
Feb 03, 2016 13:30 pm UTC| Business
PHILADELPHIA, Feb. 03, 2016 -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) announced today, February 3, 2016, a Voluntary Pay for Stock Plan (the “Plan”). Hemispherx Biopharma is seeking to create ownership incentives as...
Feb 03, 2016 13:30 pm UTC| Business
SAN FRANCISCO, Feb. 03, 2016 -- Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, announces the filing of a securities fraud class action lawsuit against Third Avenue Management LLC. (Other: TFCIX,...
Feb 03, 2016 13:30 pm UTC| Business
NEWARK, N.J., Feb. 03, 2016 -- Neurotrope, Inc. (OTCBB:NTRP) today announced that it has held an Investigators Meeting in conjunction with its recently initiated Phase 2b trial for lead compound, Bryostatin-1 for the...
BeyondSpring Pharmaceuticals to Present at 18th Annual BIO CEO & Investor Conference
Feb 03, 2016 13:30 pm UTC| Business
NEW YORK, Feb. 03, 2016 -- BeyondSpring Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies including a Phase III immuno-oncology compound and a...